Biomerica Enters Service Agreement To Develop IVD Assays
I'm LongbridgeAI, I can summarize articles.Biomerica, Inc. (BMRA) has entered a three-year Master Services Agreement with a private life science company to develop proprietary in vitro diagnostic (IVD) assays. The deal includes an initial development target fee exceeding $1.75 million via multiple statements of work, with automatic one-year renewals. Development activities will occur at Biomerica's FDA-licensed facility. At the time of reporting, BMRA shares were trading at $2.36, down 2.88%.
(RTTNews) - Biomerica, Inc. (BMRA), a biomedical company and provider of Contract Development and Manufacturing Organization (CDMO) services for healthcare market, has entered into a Master Services Agreement or MSA with a private life science company to develop proprietary in vitro diagnostic (IVD) assays.
The deal offers an initial development target fee of over $1.75 million through several statements of work (SOWs).
The contract initially is for three years, with automatic one-year renewal.
All the development activities under the agreement will be carried out at Biomerica's FDA-licensed facility. BMRA is currently trading at $2.36, down 2.88%
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.